EMEA and EUnetHTA start collaboration on European Public Assessment Report contribution to relative effectiveness assessments

The European Medicines Agency (EMEA) and representatives from the European network for Health Technology Assessment (EUnetHTA) Joint Action met in London, UK, last week for the first of a series of workshops.

This initiates a new collaboration, in which the two groups will be considering how the European Public Assessment Report (EPAR) could make a better contribution to the assessment of relative effectiveness by health technology assessment bodies in the European Union member states.

Relative effectiveness assessments are increasingly used in the member states to help policy makers to identify the most valuable medicines. The collaboration between the EMEA and EUnetHTA addresses one of the recommendations made by the Pharmaceutical Forum to improve the availability and best use of data relevant to relative effectiveness assessment.